ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Nonprescription Products may examine issues surrounding actual-use trials for OTC drugs at an advisory committee meeting later this year
You may also be interested in...
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says